PROVETOP

Mouse GPA Protein

Catalog No: GPA-MF001

Species
Mouse
Expression System
HEK293
Tag
an hFc (IgG1)

Product overview

Recombinant Mouse GPA Protein is expressed in HEK293 cells with an hFc (IgG1) tag at the C-terminus. It contains amino acid residues Met1-Val108 (UniProt accession: P14220).

Product Details

Molecular Aliases
Glycophorin-A; Glycophorin A; PAS-2; CD235a; GPA; GPErik; GpMiIII; GPSAT; GYPA; HGpMiIII; HGpMiV; HGpMiX; HGpMiXI; HGpSta(C); MNS; CD235a; MN;PAS2
Protein Length
Met1-Val108
Expression System
HEK293
Theoretical Molecular Weight
The protein has a predicted MW of 38.1 kDa. Due to glycosylation, the protein migrates to 68-75 kDa based on Bis-Tris PAGE result.
Purity
> 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
Endotoxin
Less than 1 EU per μg by the LAL method.
Buffer / Formulation
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
State
Lyophilized
Storage Conditions
-20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Reconstitution Advice
Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.

Data Display

Bis-Tris PAGE
GPA-MF001 Bis-Tris-PAGE-white result

Mouse GPA on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC
GPA-MF001 SEC-HPLC result

The purity of Mouse GPA is greater than 95% as determined by SEC-HPLC.

Background

Granulomatosis with polyangiitis (GPA) presents a wide spectrum of manifestations from the common respiratory symptoms to infrequent neurological and cardiac complications. The challenge in diagnosis and management makes the rapidly progressive disorder one of the most challenging dilemmas in clinical medicine. The ultimate goal is an improved prognosis through outcome measures which assesses the disease control with minimal adverse effects of intensive immunosuppressive regimens, an integral part of the clinical approach to improve the quality of life of GPA patients.

References

  1. Grygiel-Górniak B, Limphaibool N, Perkowska K, Puszczewicz M. Clinical manifestations of granulomatosis with polyangiitis: key considerations and major features. Postgrad Med. 2018 Sep;130(7):581-596. doi: 10.1080/00325481.2018.1503920. Epub 2018 Aug
  2. PMID:
  3. Note: HPLC results always come from liquid protein, due to absorption peak interference of trehalose in lyophilized powder.

Have questions about this product?

Our technical team can help with product selection, application questions and order support.

Contact Technical Support